Key result
ADAMTS-4 inhibited VEGF-stimulated VEGF receptor 2 phosphorylation, differentiation, and migration in human dermal microvascular endothelial cells, suggesting it is a novel anti-angiogenic molecule.
Hypothesis-generating for anti-angiogenic strategies in vascular disease; does not support clinical adoption without in vivo validation.
Angiogenesis is an indispensable mechanism in development and in many pathologies, including cancer, synovitis and aberrant wound healing. Many angiogenic stimulators and inhibitors have been investigated, and some have progressed to the clinic. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) is a group of multifunctional proteinases. ADAMTS-1 and ADAMTS-8 have been reported to be anti-angiogenic. Here, we provide evidence that ADAMTS-4, like ADAMTS-1, is expressed by endothelial cells and binds to vascular endothelial groth factor (VEGF). Moreover, ADAMTS-4 inhibited human dermal microvascular endothelial cells (HuDMEC) VEGF-stimulated VEGF receptor (R) R2 phosphorylation, differentiation and migration, suggesting that ADAMTS-4 may be a novel anti-angiogenic molecule.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2012) studied Angiogenesis. ADAMTS-4 was evaluated on VEGF receptor 2 phosphorylation, differentiation and migration. ADAMTS-4 inhibited VEGF-stimulated VEGF receptor 2 phosphorylation, differentiation, and migration in human dermal microvascular endothelial cells, suggesting it is a novel anti-angiogenic molecule.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: